An upstart jumps almost overnight from preclinical to PhI with a $35M Takeda deal and a buyout option
Here’s a nontraditional way to set up a biotech company and shoot straight at a buyout.
About six years ago, Ingrid Swanson Pultz advised a group of students at the University of Washington who took on the challenge of using 3D structure protein design tech to develop a new therapy for celiac disease, marked by a severe reaction to gluten.
Starting out with an enzyme that could withstand the harsh, acidic environment of the stomach, they engineered it specifically to go after fragments of gluten that trigger a gut reaction. And they did well, winning a prestigious competition.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.